Viatris Inc (VTRS)
11.62
+0.16
(+1.44%)
USD |
NASDAQ |
Nov 05, 16:00
11.76
+0.14
(+1.20%)
After-Hours: 20:00
Viatris Enterprise Value: 29.63B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 29.63B |
| November 01, 2024 | 29.83B |
| October 31, 2024 | 29.80B |
| October 30, 2024 | 30.15B |
| October 29, 2024 | 29.97B |
| October 28, 2024 | 29.99B |
| October 25, 2024 | 29.61B |
| October 24, 2024 | 29.66B |
| October 23, 2024 | 29.74B |
| October 22, 2024 | 29.89B |
| October 21, 2024 | 29.77B |
| October 18, 2024 | 29.99B |
| October 17, 2024 | 29.93B |
| October 16, 2024 | 30.06B |
| October 15, 2024 | 30.09B |
| October 14, 2024 | 29.55B |
| October 11, 2024 | 29.54B |
| October 10, 2024 | 29.48B |
| October 09, 2024 | 29.57B |
| October 08, 2024 | 29.47B |
| October 07, 2024 | 29.48B |
| October 04, 2024 | 29.79B |
| October 03, 2024 | 29.60B |
| October 02, 2024 | 29.65B |
| October 01, 2024 | 29.67B |
| Date | Value |
|---|---|
| September 30, 2024 | 29.81B |
| September 27, 2024 | 29.74B |
| September 26, 2024 | 29.83B |
| September 25, 2024 | 29.41B |
| September 24, 2024 | 29.62B |
| September 23, 2024 | 29.65B |
| September 20, 2024 | 29.55B |
| September 19, 2024 | 30.16B |
| September 18, 2024 | 30.16B |
| September 17, 2024 | 30.06B |
| September 16, 2024 | 30.05B |
| September 13, 2024 | 29.87B |
| September 12, 2024 | 29.98B |
| September 11, 2024 | 29.49B |
| September 10, 2024 | 29.29B |
| September 09, 2024 | 29.24B |
| September 06, 2024 | 29.41B |
| September 05, 2024 | 29.88B |
| September 04, 2024 | 30.02B |
| September 03, 2024 | 30.15B |
| August 30, 2024 | 30.37B |
| August 29, 2024 | 30.15B |
| August 28, 2024 | 30.16B |
| August 27, 2024 | 29.91B |
| August 26, 2024 | 29.98B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
18.93B
Minimum
Mar 12 2020
47.41B
Maximum
Dec 31 2020
31.20B
Average
30.84B
Median
Enterprise Value Benchmarks
| Lexicon Pharmaceuticals Inc | 225.13M |
| Eli Lilly and Co | 792.96B |
| Amgen Inc | 221.77B |
| Gilead Sciences Inc | 132.34B |
| Perspective Therapeutics Inc | 530.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -326.40M |
| Revenue (Quarterly) | 3.797B |
| Total Expenses (Quarterly) | 3.913B |
| EPS Diluted (Quarterly) | -0.27 |
| Gross Profit Margin (Quarterly) | 38.07% |
| Profit Margin (Quarterly) | -8.60% |
| Earnings Yield | -4.73% |
| Operating Earnings Yield | 2.75% |
| Normalized Earnings Yield | -2.130 |